The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Harley Street

3 May 2016 09:01

RNS Number : 0126X
Advanced Oncotherapy PLC
03 May 2016
 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Update on Harley Street

 

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, notes that a number of shareholders have raised concerns that a planning application submitted by Howard de Walden Estates Limited for 141-143 Harley Street was withdrawn in January 2016 and that this will have an impact on the Company's progress.

 

Howard de Walden Estates and Advanced Oncotherapy have confirmed that the withdrawn planning application was for 'use swap' purposes only and did not involve any works to the building which are part of creating the Proton Beam Therapy Facility.

 

The application was withdrawn as the area of the facility had grown in size, as referenced in the update provided on 28 July 2015, and since the original 50 year lease agreement was signed with Howard de Walden Estates in January 2015, the available space for the centre has increased by approximately 50% allowing for an additional treatment room and additional imaging facilities.

 

Howard de Walden Estates are satisfied that progress for the site remains on track. The total cost of the redevelopment is being borne by Howard de Walden Estates.

 

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Michael Sinclair, Chief Executive Office

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

 

 

 

Stockdale Securities (Nomad & Joint Broker)

 

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

 

 

Beaufort Securities (Joint Broker)

 

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

    

 

 

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers. In October 2015 the Company signed a joint venture agreement with CircleHealth to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSUSWDFMSEII
Date   Source Headline
26th Apr 20177:00 amRNSConversion of Convertible Loan Notes
25th Apr 20175:48 pmRNSAdditional financing agreement
25th Apr 20177:00 amRNSDirector/PDMR Shareholding
18th Apr 20177:00 amRNSConversion of loan notes
13th Apr 20177:00 amRNSDirector Dealing
11th Apr 20177:00 amRNSConversion of loan notes
7th Apr 20177:00 amRNSConversion of loan notes
6th Apr 20172:07 pmRNSTotal Voting Rights
4th Apr 20174:01 pmRNSDirector Dealing
4th Apr 201710:05 amRNSDirector Dealing - Replacement
4th Apr 20177:00 amRNSDirector Dealing
31st Mar 20175:10 pmRNSResult of General Meeting
27th Mar 20177:00 amRNSAdditional financing agreement
21st Mar 20177:00 amRNSHolding(s) in Company
15th Mar 20177:15 amRNSHardman Research: Delivery of LIGHT
10th Mar 20177:00 amRNSPosting of Circular, Notice of GM and Update
6th Mar 20173:30 pmRNSInvestor presentation and Update
28th Feb 20177:00 amRNSConversion of convertible loan notes
24th Feb 20177:00 amRNSUpdate on financing and Harley Street
22nd Feb 20177:00 amRNSFinancing agreement
16th Feb 20177:00 amRNSInvestor presentation
8th Feb 20177:00 amRNSSignificant shareholder
6th Feb 20177:00 amRNSSinophi update
26th Jan 20177:00 amRNSDirectorate Changes
24th Jan 20177:00 amRNSSinophi Update
23rd Jan 20177:00 amRNSNon-dilutive financing plan update
3rd Jan 201711:41 amRNSDirector Dealing
29th Dec 20162:13 pmRNSDirector Dealing
29th Dec 201612:51 pmRNSSignificant Shareholding Dealing
22nd Dec 20161:36 pmRNSDirector Dealing
22nd Dec 20167:00 amRNSFurther progress in LIGHT technical development
21st Dec 201611:47 amRNSDirector Dealing
21st Dec 20167:00 amRNSDirector Dealing
20th Dec 20167:00 amRNSDirector dealing
15th Dec 20167:00 amRNSVideo of LIGHT system and testing facilities
30th Nov 20163:39 pmRNSOperational Update
29th Nov 201611:29 amRNSDirector Dealing - replacement
29th Nov 201610:06 amRNSDirector Dealing
24th Nov 20164:24 pmRNSUpdate on Harley Street and Sinophi
15th Nov 20165:45 pmRNSHolding(s) in Company
8th Nov 20167:00 amRNSChange of Adviser
7th Nov 20162:55 pmRNSExercise of Options and Issue of Shares
1st Nov 20167:00 amRNSDirectorate Change
1st Nov 20167:00 amRNSResult of Open Offer
31st Oct 20167:00 amRNSIndustrialisation agreement with Thales
27th Oct 20167:00 amRNSDirectorate Change
25th Oct 20164:59 pmRNSREPLACEMENT: Director Dealing
25th Oct 20163:01 pmRNSDirector Dealing
19th Oct 20167:00 amRNSHarley Street planning permission granted
14th Oct 20167:00 amRNSOpen Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.